| AbCellera is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies to address pandemics and common diseases. Co.'s full-stack, artificial intelligence-, or AI, powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. Rather than advancing its own clinical pipeline of drug candidates, Co. forges partnerships with drug developers of all sizes, from pharmaceutical to small biotechnology companies. In a collaboration with Eli Lilly and Company, Co. has applied its technology stack to co-develop LY-CoV555, a potential antibody therapy to treat and prevent COVID-19. We show 1 historical shares outstanding datapoints in our ABCL shares outstanding history coverage, used to compute ABCL market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ABCL market cap history over the course of time is important for investors
interested in comparing ABCL's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ABCL versus a peer is one thing; comparing
ABCL market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ABCL can fluctuate over the course of history.
With this page we aim to empower investors researching ABCL by allowing them to research the ABCL market cap history.